← Ishga qaytish
Ushbu ish iqtibos qilgan ishlar
145 ta ish
Ish: Disrupting immune silence: Noncoding RNAs targeting the programmed cell death protein 1/programmed cell death ligand 1 axis in tumor immunity
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Yoshiko Iwai, Masayoshi Ishida, Yoshimasa Tanaka +3
MaqolaOchiq kirish20025 iqtibosABITargeting non-coding RNAs to overcome cancer therapy resistance
Baoqing Chen, Mihnea P. Dragomir, Yang Chen +3
Sharh maqolaOchiq kirish20224 iqtibosABICircRNAs: role in human diseases and potential use as biomarkers
Lorena Verduci, Emilio Tarcitano, Sabrina Strano +2
Sharh maqola20214 iqtibosABIMechanisms of Tumor Cell–Intrinsic Immune Evasion
Stefani Spranger, Thomas F. Gajewski
MaqolaOchiq kirish20173 iqtibosABILIN28/ <i>let-7</i> /PD-L1 Pathway as a Target for Cancer Immunotherapy
Yanlian Chen, Chen Xie, Xiaohui Zheng +4
Maqola20193 iqtibosABINon‐coding RNAs in cancer immunotherapy: Predictive biomarkers and targets
Sharh maqola20233 iqtibosABILncRNA KCNQ1OT1 sponges miR-15a to promote immune evasion and malignant progression of prostate cancer via up-regulating PD-L1
Qihua Chen, Bo Li, De-Guo Liu +3
MaqolaOchiq kirish20202 iqtibosABIImmunomodulatory MicroRNAs in cancer: targeting immune checkpoints and the tumor microenvironment
Hany A. Omar, Ahmed T. El‐Serafi, Fatema Hersi +5
Sharh maqolaOchiq kirish20192 iqtibosABIMir-21 Suppression Promotes Mouse Hepatocarcinogenesis
Marta Correia de Sousa, Nicolas Calo, Cyril Sobolewski +12
Maqola20212 iqtibosABIThe role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy
Wenxiao Jiang, Shuya Pan, Xin Chen +2
Sharh maqola20212 iqtibosABIThe role of circular RNAs in regulating resistance to cancer immunotherapy: mechanisms and implications
Yu Ma, Ting Wang, Xudong Zhang +2
Sharh maqola20242 iqtibosABINoncoding RNAs in cancer immunity: functions, regulatory mechanisms, and clinical application
Le Zhang, Xiaonan Xu, Xiulan Su
Sharh maqola20202 iqtibosABI